[go: up one dir, main page]

NO20084456L - Organiske forbindelser - Google Patents

Organiske forbindelser

Info

Publication number
NO20084456L
NO20084456L NO20084456A NO20084456A NO20084456L NO 20084456 L NO20084456 L NO 20084456L NO 20084456 A NO20084456 A NO 20084456A NO 20084456 A NO20084456 A NO 20084456A NO 20084456 L NO20084456 L NO 20084456L
Authority
NO
Norway
Prior art keywords
organic compounds
stereoisomers
compound
indicated
formula
Prior art date
Application number
NO20084456A
Other languages
English (en)
Inventor
Roger John Taylor
Robin Alec Fairhurst
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084456L publication Critical patent/NO20084456L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en forbindelse med formel (I), eller stereoisomerer eller farmasøytisk akseptable salter derav, (I) der R1a, R1b, R2a,R2b, U1, U2, X1, X2 og L er som angitt.
NO20084456A 2006-04-21 2008-10-22 Organiske forbindelser NO20084456L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607950.3A GB0607950D0 (en) 2006-04-21 2006-04-21 Organic compounds
PCT/EP2007/003439 WO2007121924A2 (en) 2006-04-21 2007-04-19 Bisadenosine compounds as adenosine a2a receptor agonists

Publications (1)

Publication Number Publication Date
NO20084456L true NO20084456L (no) 2008-12-09

Family

ID=36581047

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084456A NO20084456L (no) 2006-04-21 2008-10-22 Organiske forbindelser

Country Status (32)

Country Link
US (1) US8193164B2 (no)
EP (1) EP2018388B9 (no)
JP (1) JP2009534341A (no)
KR (1) KR20080112399A (no)
CN (1) CN101437829B (no)
AR (1) AR060606A1 (no)
AT (1) ATE502040T1 (no)
AU (1) AU2007241347A1 (no)
CA (1) CA2648037A1 (no)
CL (1) CL2007001132A1 (no)
CR (1) CR10328A (no)
CY (1) CY1111568T1 (no)
DE (1) DE602007013203D1 (no)
DK (1) DK2018388T3 (no)
EC (1) ECSP088837A (no)
ES (1) ES2363255T3 (no)
GB (1) GB0607950D0 (no)
GT (1) GT200800218A (no)
HR (1) HRP20110445T1 (no)
IL (1) IL194398A0 (no)
MA (1) MA30404B1 (no)
MX (1) MX2008013398A (no)
NO (1) NO20084456L (no)
PE (1) PE20071228A1 (no)
PL (1) PL2018388T3 (no)
PT (1) PT2018388E (no)
RU (1) RU2008145715A (no)
SI (1) SI2018388T1 (no)
TN (1) TNSN08409A1 (no)
TW (1) TW200813074A (no)
WO (1) WO2007121924A2 (no)
ZA (1) ZA200808103B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2909277A1 (en) 2006-04-04 2007-10-11 Kevan M. Shokat Kinase antagonists
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) * 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
CN101827847A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物
SG10201605472WA (en) 2008-01-04 2016-09-29 Intellikine Llc Certain Chemical Entities, Compositions And Methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI659956B (zh) 2011-01-10 2019-05-21 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
HK1198475A1 (en) 2011-07-19 2015-05-08 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI657085B (zh) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 雜環化合物及其用途
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
US4954504A (en) 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
EP0267878A1 (en) 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-cyclopentyl-substituted adenine derivatives
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
EP0550631B1 (en) 1990-09-25 1997-01-02 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
PT909270E (pt) 1996-01-02 2002-11-29 Aventis Pharma Inc Processo para a preparacao de 2,4-dihidroxipiridina e de 2,4-dihidroxi-3-nitropiridina
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP0991414A4 (en) 1997-05-09 2002-10-02 Univ Pennsylvania METHODS AND COMPOSITIONS FOR REDUCING ISCHAEMIC DAMAGE IN THE HEART BY ADMINISTRATING ADENOSINE RECEPTORAGONISTS AND ANTAGONISTS
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
NZ509030A (en) 1998-06-23 2003-07-25 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
DE69932173T2 (de) 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
BR9917000A (pt) 1998-12-31 2001-12-11 Aventis Pharm Prod Inc Processo para preparar derivados dedesaza-adenosina n6-substituìda
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AU2002219497B2 (en) 2001-01-16 2004-08-26 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
JP2006515829A (ja) 2002-04-10 2006-06-08 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
JP2007517019A (ja) 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
KR20070004792A (ko) 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
JP2007536241A (ja) 2004-05-03 2007-12-13 ユニバーシティ オブ バージニア パテント ファウンデーション 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
KR101313027B1 (ko) * 2004-06-23 2013-10-02 신타 파마슈티칼스 코프. 암 치료용 비스(티오-히드라지드 아미드) 염
JP4642847B2 (ja) 2004-07-28 2011-03-02 キャン−ファイト・バイオファーマ・リミテッド シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
KR20070050484A (ko) 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ａ1 및 ａ3 아데노신 수용체 아고니스트로서의 퓨린 유도체
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US7951810B2 (en) 2005-02-04 2011-05-31 Millennium Pharmaceuticals, Inc. Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
DK1959939T3 (da) 2005-11-30 2012-04-23 Can Fite Biopharma Ltd Anvendelse af a3-adenosinreceptoragonist i behandlingen af osteoarthritis
ES2360632T3 (es) 2006-01-26 2011-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Moduladores alostéricos del receptor a3 de adenosina.
CN103288835A (zh) 2006-02-02 2013-09-11 千禧药品公司 E1活化酶抑制剂
US20080027022A1 (en) 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
GB0607951D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
WO2008124150A1 (en) 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
EP2170401A1 (en) 2007-06-29 2010-04-07 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
CN101827847A (zh) 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物
US20090181934A1 (en) 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
US8183225B2 (en) 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
EA201001135A1 (ru) 2008-01-09 2011-02-28 ПиДжиИксХЭЛС ЭлЭлСи Интратекальное лечение невропатической боли агонистами ar

Also Published As

Publication number Publication date
KR20080112399A (ko) 2008-12-24
WO2007121924A3 (en) 2008-09-04
CA2648037A1 (en) 2007-11-01
IL194398A0 (en) 2009-08-03
PE20071228A1 (es) 2008-01-24
ECSP088837A (es) 2008-11-27
CL2007001132A1 (es) 2008-05-23
GB0607950D0 (en) 2006-05-31
SI2018388T1 (sl) 2011-07-29
HRP20110445T1 (hr) 2011-07-31
CN101437829A (zh) 2009-05-20
MA30404B1 (fr) 2009-05-04
EP2018388A2 (en) 2009-01-28
AU2007241347A1 (en) 2007-11-01
US8193164B2 (en) 2012-06-05
PL2018388T3 (pl) 2011-08-31
EP2018388B9 (en) 2011-10-05
CY1111568T1 (el) 2015-10-07
CR10328A (es) 2008-11-18
PT2018388E (pt) 2011-06-27
JP2009534341A (ja) 2009-09-24
TW200813074A (en) 2008-03-16
TNSN08409A1 (en) 2010-04-14
ATE502040T1 (de) 2011-04-15
ES2363255T3 (es) 2011-07-28
DE602007013203D1 (de) 2011-04-28
EP2018388B1 (en) 2011-03-16
MX2008013398A (es) 2008-11-04
US20100190784A1 (en) 2010-07-29
GT200800218A (es) 2008-12-15
WO2007121924A2 (en) 2007-11-01
AR060606A1 (es) 2008-07-02
ZA200808103B (en) 2009-07-29
CN101437829B (zh) 2012-03-21
DK2018388T3 (da) 2011-06-27
RU2008145715A (ru) 2010-05-27

Similar Documents

Publication Publication Date Title
NO20084456L (no) Organiske forbindelser
TNSN08407A1 (en) Organic compounds
PH12012501711A1 (en) [5,6] heterocyclic compound
EA200801381A1 (ru) Производные пиримидина
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
MA32456B1 (fr) Dérivé hétérocyclique contenant du soufre ayant une activité inhibant la b-sécrétase
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
GB0607954D0 (en) Organic compounds
NO20084583L (no) Makrosykliske kinase-inhibitorer
NO20076624L (no) Syklisk aminderivat med substituert alkylgruppe
NO20076054L (no) Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
JO2681B1 (en) Indole derivatives
NO20064077L (no) Kemokinreseptorantagonister
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
TW201129556A (en) Novel antiplatelet agent
NO20076055L (no) Imidazo- og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
NO20075768L (no) Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90
WO2008146665A1 (ja) 有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子並びに有機エレクトロルミネッセンス表示装置
WO2009020140A1 (ja) アダマンチルウレア誘導体
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
NO20082877L (no) Forloperforbindelse til radioaktiv halogenmerket organisk forbindelse
NO20081888L (no) Triazolforbindelser som lipoksygenaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application